B. Serum Institute of India
Feedback Drugs Controller General of India (DCGI) which is country's apex drug regulator has directed Serum Institute of India SII to suspend the new recruitments which were about to happen for recent phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine till further orders.